Impact of Tyrosine Kinase Inhibitors on Glucose Level and Lipid Metabolism in Chronic Myeloid Leukemia Patients

to known the impact of drugs that used in CML pt as TKIs on glucose and lipid metabolism

Not Yet Recruiting

Trial opening soon.

Key information

Conditions

Chronic Myeloid Leukemia Bone Marrow Diseases Chronic Disease Disease Attributes Hematologic Diseases Hemic and Lymphatic Diseases Leukemia Leukemia, Myelogenous, Chronic, BCR-ABL Positive Leukemia, Myeloid Myeloproliferative Disorders Neoplasms Neoplasms by Histologic Type Pathologic Processes Pathological Conditions, Signs and Symptoms

Sex eligibility

All sexes

Study type

Observational

About this study

to known the impact of drugs that used in CML pt as TKIs on glucose and lipid metabolism and how danger they drugs be

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

CML patients free medical history

Exclusion criteria

diabetic

Treatment and study plan

Tyrosine kinase Inhibitors (Imatinib & Nilotinib)

Drug

these drugs used in CML only

Primary outcomes

Change in HbA1c levels in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors

Time frame: Baseline and 3, 6, 9, and 12 months

Assessment of change in HbA1c levels in CML patients treated with TKIs.

Secondary outcomes

Change in lipid profile in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors

Time frame: Baseline and 3, 6, 9, and 12 months

Assessment of changes in lipid profile including total cholesterol, triglycerides, LDL, and HDL in CML patients treated with TKIs.

Study contacts

Contact information is provided by the study sponsor or research team.

Nancy Atef Abdou, doctor

CONTACT

[email protected]

01027607363 ext. 01153253658

mai mostafa kamal, prof

CONTACT

Sponsors and collaborators

Lead sponsor

Assiut University

Other

Registry information

Official study title

Impact of Tyrosine Kinase Inhibitors on Glucose and Lipid Metabolism in Chronic Myeloid Leukemia

Important dates

Study start: 2026
Primary completion: 2027
Study completion: 2028
First posted: Feb 17, 2026
Registry last updated: Feb 18, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Not Yet Recruiting